Cryoport, Inc. (CYRX)
$
6.08
-0.01 (-0.16%)
Key metrics
Financial statements
Free cash flow per share
-0.6852
Market cap
310.4 Million
Price to sales ratio
1.3593
Debt to equity
0.6238
Current ratio
5.2905
Income quality
0.1422
Average inventory
23 Million
ROE
-0.2759
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. In the fiscal year 2023 the total costs and expenses for the company are $359,251,000.00 reflecting its overall spending and operational overhead. The company reported selling, general, and administrative expenses of $148,978,000.00 indicating its operational overhead costs. The operating income ratio is -0.57 which highlights the company's operational profitability margin. Furthermore, the income before tax ratio stands at -0.54 reflecting the pre-tax margin associated with its activities. The company's logistics offerings include the Cryoportal, a cloud-based logistics management platform for shipment management, encompassing order entry, document preparation, customs documentation, courier management, and real-time shipment tracking. Additionally, CryoPort Express Shippers are utilized to maintain the stability of biologic commodities during shipping. The company also provides informative dashboards and validation documentation through the data collected by the SmartPak Condition Monitoring System, alongside vacuum-insulated aluminum dewars and cryogenic freezer systems. Beyond shipping logistics, it offers biological specimen cryopreservation storage, sample archiving, monitoring, and tracking, as well as managing the transportation and logistics of frozen biological specimens. With a market capitalization of $303,455,232.00 the company is classified as a small-cap player. It is a key player in the Integrated Freight & Logistics industry, contributing significantly to the overall market landscape. The stock is affordable at $6.65 making it suitable for budget-conscious investors. However, it should be noted that the stock has a low average trading volume of 416,621.00 indicating lower market activity. Additionally, it belongs to the Industrials sector, driving innovation and growth within its field. Cryoport's range of services, including logistics management and consulting, positions it strategically to meet the needs of biopharma/pharma, animal health, and human reproductive medicine markets, thus reinforcing its importance in the global life sciences ecosystem.
What is Cryoport, Inc. (CYRX)'s stock forecast?
Analysts predict Cryoport, Inc. stock to fluctuate between $4.58 (low) and $20.11 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cryoport, Inc.'s market capitalization?
As of 2025-04-01, Cryoport, Inc.'s market cap is $303,455,232, based on 49,910,400 outstanding shares.
How does Cryoport, Inc. compare to competitors like Amazon.Com Inc?
Compared to Amazon.Com Inc, Cryoport, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cryoport, Inc. (CYRX) stock?
To buy Cryoport, Inc. (CYRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CYRX. Place an order (Market, Limit, etc.).
What is the best time to invest in Cryoport, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Cryoport, Inc. perform in the last earnings report?
Revenue: $228,385,000 | EPS: -$2.49 | Growth: 12.67%.
Where can I find Cryoport, Inc.'s investor relations reports?
Visit https://www.cryoport.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cryoport, Inc.?
You can explore historical data from here
What is the all-time high and low for Cryoport, Inc. stock?
All-time high: $86.30 (2021-11-08) | All-time low: $4.58 (2025-03-04).
What are the key trends affecting Cryoport, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Cryoport, Inc. (NASDAQ:CYRX ) Strategic Agreement and Transaction with DHL Group Call March 31, 2025 8:30 AM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Tom Heinzen - Vice President, Corporate Development & Investor Relations Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Paul Knight - KeyBanc Tejas Savant - Morgan Stanley David Larsen - BTIG David Saxon - Needham Operator Good morning, and welcome to Cryoport's Investor Conference Call. All participants will start in a listen-only mode.
prnewswire.com
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.
prnewswire.com
NASHVILLE, Tenn. , March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers.
seekingalpha.com
Start Time: 17:00 January 1, 0000 5:41 PM ET Cryoport, Inc. (NASDAQ:CYRX ) Q4 2024 Earnings Conference Call March 04, 2025, 17:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP IR and Corporate Development Todd Fromer - IR, KCSA Strategic Communications Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Puneet Souda - Leerink Partners David Saxon - Needham Subbu Nambi - Guggenheim David Larson - BTIG Richard Baldry - Roth Capital Kyle Crews - UBS Matt Stanton - Jefferies Operator Good afternoon, and welcome to Cryoport's Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will start in a listen-only mode.
zacks.com
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.
prnewswire.com
NASHVILLE, Tenn. , Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets close.
zacks.com
MC, LFST, EAT, CYRX and HCP have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2024.
prnewswire.com
New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in Dallas NASHVILLE, Tenn. , Jan. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today unveiled its Cryoport Express® Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings.
prnewswire.com
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn.
prnewswire.com
All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn. , Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological Solutions ("MVE"), a Cryoport company and the leading global manufacturer of high-quality cryogenic freezers and dewars, has officially registered all three of its manufacturing facilities (located in Ball Ground, Georgia; New Prague, Minnesota; and Chengdu, China) with the U.S. Food and Drug Administration ("FDA").
See all news
